Antiviral Drug

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 39438 Experts worldwide ranked by ideXlab platform

Sina Bavari - One of the best experts on this subject based on the ideXlab platform.

Erik De Clercq - One of the best experts on this subject based on the ideXlab platform.

  • the next ten stories on Antiviral Drug discovery part e advents advances and adventures
    Medicinal Research Reviews, 2011
    Co-Authors: Erik De Clercq
    Abstract:

    This review article presents the fifth part (part E) in the series of stories on Antiviral Drug discovery. The ten stories belonging to this fifth part are dealing with (i) aurintricarboxylic acid; (ii) alkenyldiarylmethanes; (iii) human immunodeficiency virus (HIV) integrase inhibitors; (iv) lens epithelium-derived growth factor as a potential target for HIV proviral DNA integration; (v) the status presens of neuraminidase inhibitors NAIs in the control of influenza virus infections; (vi) the status presens on respiratory syncytial virus inhibitors; (vii) tricyclic (1,N-2-ethenoguanine)-based acyclovir and ganciclovir derivatives; (viii) glycopeptide antibiotics as Antivirals targeted at viral entry; (ix) the potential (off-label) use of cidofovir in the treatment of polyoma (JC and BK) virus infections; and (x) finally, thymidine phosphorylase as a target for both Antiviral and anticancer agents. © 2009 Wiley Periodicals, Inc. Med Res Rev, 31, No. 1, 118–160, 2010

  • Antiviral Drug discovery ten more compounds and ten more stories part b
    Medicinal Research Reviews, 2009
    Co-Authors: Erik De Clercq
    Abstract:

    This review article that complements the previous review article on "The discovery of Antiviral agents: ten different compounds, ten different stories" presents ten more compounds and ten more stories in which I have been closely involved at one or another point of my scientific career: (i) interferon (IFN) (in particular, IFN-beta); (ii) poly(I).poly(C); (iii) suramin; (iv) novel acyclic nucleoside phosphonates; (v) the double proDrug of [9-(2-phosphonomethoxyethyl)guanine]; (vi) cyclic nucleoside phosphonates; (vii) picornavirus inhibitors; (viii) human immunodeficiency virus (HIV) co-receptor inhibitors; (ix) nonimmunosuppressive cyclosporin A analogues; and (x) bicyclic (furanopyrimidine) nucleoside analogues. With the exception of the HIV co-receptor CCR5 inhibitor none of the compounds described here have already been marketed (for the indication they were initially developed). Successful Antiviral Drug development depends on the interplay of three disciplines, chemistry, biology/medicine, and industry, crucial factors being open mindedness for the unexpected, preparedness to explore serendipitous observations, and perseverance (in trying) to overcome the hurdles or setbacks inevitably compounding any Drug development.

  • A guided tour through the Antiviral Drug field
    Future Virology, 2006
    Co-Authors: Erik De Clercq
    Abstract:

    Approximately 40 compounds have been formally licensed for clinical use as Antiviral Drugs, with half of these in use for the treatment of HIV infections. The remaining have been approved for use in the therapy of herpes virus (herpes simplex virus, varicella zoster virus and cytomegalovirus), hepadnavirus, hepacivirus and myxovirus (influenza and respiratory syncytial virus) infections. New compounds are in clinical development or under preclinical evaluation, and again, half of these are intended to target HIV infections. However, quite a number of important viral pathogens (i.e., human papillomavirus, hepatitis C virus and hemorrhagic fever viruses) remain in need of effective and/or improved Antiviral therapies.

  • use of digoxigenin labelled probes for the quantitation of hbv dna in Antiviral Drug evaluation
    Journal of Virological Methods, 1999
    Co-Authors: Chunxiao Ying, Jaan Pelt, Erik De Clercq, Johan Neyts
    Abstract:

    Abstract The use of digoxigenin-labelled probes was studied for quantitation of HBV-DNA during Antiviral Drug evaluation. Digoxigenin (dig)-labelled probes were generated either via incorporation of dig-dUTP in a polymerase chain reaction (PCR) or a random priming reaction. Using the PCR-labelled probe (delineating a 523 bp fragment in the core gene of the HBV) as little as 1 pg of immobilized HBV-DNA could be detected following an 8 h exposure of the hybridized membrane. A close correlation (r=0.95) was found between the amount of HBV-DNA (range 2.5–200 pg) and the signal generated by the probe hybridized to its target DNA. By using a probe that was labelled with digoxigenin via random priming, the minimal quantity of immobilized HBV plasmid DNA that could be detected following an 8 h exposure was 4 pg, whereas a 32P-labelled probe, generated in parallel by random priming, allowed the detection of 16 pg of HBV plasmid DNA following a 4-day exposure. The PCR-generated digoxigenin-labelled probe proved to be useful for Antiviral Drug evaluation, i.e. to detect HBV-DNA in total cellular DNA from HBV-positive hepatoma cells (HepG2.2.15) that had either been treated with reference Antiviral agents or left untreated. The 50% effective concentrations (EC50) that were calculated for inhibition of HBV-DNA production by lamivudine (3TC), penciclovir (PCV), lobucavir (LBV), adefovir (PMEA) and tenofovir (PMPA) were comparable to those reported in the literature. The use of digoxigenin-labelled probes thus appears to be a simple, convenient, rapid, reliable and non-radioactive method for use for anti-HBV screening. In addition, and in contrast to 32P-labelled probes, digoxigenin-labelled probes can be stored for >1 year without loss of specific activity, which makes these probes particularly attractive for large-scale Antiviral Drug evaluation purposes.

Allison L. Totura - One of the best experts on this subject based on the ideXlab platform.

Pranab K. Mohapatra - One of the best experts on this subject based on the ideXlab platform.

  • A Chronicle of SARS-CoV-2: Seasonality, Environmental Fate, Transport, Inactivation, and Antiviral Drug Resistance
    Journal of Hazardous Materials, 2020
    Co-Authors: Manish Kumar, Payal Mazumder, Sanjeeb Mohapatra, Alok Kumar Thakur, Kiran Dhangar, Kaling Taki, Santanu Mukherjee, Arbind Kumar Patel, Prosun Bhattacharya, Pranab K. Mohapatra
    Abstract:

    Abstract In this review, we present the environmental perspectives of the viruses and Antiviral Drugs related to SARS-CoV-2. The present review paper discusses occurrence, fate, transport, susceptibility, and inactivation mechanisms of viruses in the environment as well as environmental occurrence and fate of Antiviral Drugs, and prospects (prevalence and occurrence) of Antiviral Drug resistance (both Antiviral Drug resistant viruses and Antiviral resistance in the human). During winter, the number of viral disease cases and environmental occurrence of Antiviral Drug surge due to various biotic and abiotic factors such as transmission pathways, human behaviour, susceptibility, and immunity as well as cold climatic conditions. Adsorption and persistence critically determine the fate and transport of viruses in the environment. Inactivation and disinfection of virus include UV, alcohol, and other chemical-base methods but the susceptibility of virus against these methods varies. Wastewater treatment plants (WWTPs) are major reserviors of Antiviral Drugs and their metabolites and transformation products. Ecotoxicity of Antiviral Drug residues against aquatic organisms have been reported, however more threatening is the development of Antiviral resistance, both in humans and in wild animal reservoirs. In particular, emergence of Antiviral Drug-resistant viruses via exposure of wild animals to high loads of Antiviral residues during the current pandemic needs further evaluation.

Seungtaek Kim - One of the best experts on this subject based on the ideXlab platform.

  • identification of Antiviral Drug candidates against sars cov 2 from fda approved Drugs
    Antimicrobial Agents and Chemotherapy, 2020
    Co-Authors: Sangeun Jeon, Jihye Lee, Inhee Choi, Soo Young Byun, Soonju Park, David Shum, Seungtaek Kim
    Abstract:

    Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved Drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential Antiviral Drug candidates against SARS-CoV-2 infection. Some Drug candidates showed very low 50% inhibitory concentrations (IC50s), and in particular, two FDA-approved Drugs-niclosamide and ciclesonide-were notable in some respects.

Related terms

Antiviral Drug - 15 days free trial to Access Experts & Abstracts